European Journal of Ophthalmology最新文献

{"title":"The prognostic role of video head-impulse test in the clinical evaluation of chronic vestibular damage: A brief case series.","authors":"Stefano Dore, Renato Patta, Giacomo Boscia, Pasquale Viggiano, Ermete Giancipoli, Andrea Melis, Antonio Pinna","doi":"10.1177/11206721251338500","DOIUrl":"https://doi.org/10.1177/11206721251338500","url":null,"abstract":"<p><p>IntroductionThe video Head Impulse Test (vHIT) is a valid tool in identifying acute vestibular damage (AVD) and cerebellar vertigo syndromes, but a diagnostic gap remains in identifying those patients who experience persistence of chronic vestibular symptoms. The aim of this brief study was to investigate the ability of vHIT combined with the Italian Dizziness Handicap Inventory (DHI) score to identify AVD patients who develop chronic vestibular deficiency.Case SeriesThe mean age of the 18 patients enrolled was 56 years (SD ± 12), and among them 10 (55.5%) were males. Improved gain was found in one-third of the cases (6, 33.3%); in addition, we observed that the vHIT 60 ms gain could predict the DHI value at follow-up (p = 0.007). Furthermore, the distribution of Overt and Covert saccades at follow-up between the two iDHI groups was significantly different (p = 0.025), with a greater number of patients without any type of corrective saccade in the low iDHI group. Furthermore, group 1 patients were found to have a significantly higher mean age compared to those of group 0 (p = 0.015), along with a lower vHIT gain at 60 ms at final follow-up (p = 0.062).ConclusionsThese results of our study showed that the vHIT 60 ms gain could predict the iDHI score, but the width and latency of the saccades were not correlated with iDHI at follow-up. In addition, patients with low iDHI score had not corrective saccades, while those with high iDHI score were significantly older than those with low iDHI.</p>","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":" ","pages":"11206721251338500"},"PeriodicalIF":1.4,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143978687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Suprachoroidal injection of a dexamethasone implant in a case of secondary macular oedema.","authors":"Pedro Neves","doi":"10.1177/11206721251337634","DOIUrl":"https://doi.org/10.1177/11206721251337634","url":null,"abstract":"<p><p>BackgroundNon-infectious uveitis (NIU) is a common ocular inflammation that frequently leads to Macular oedema (MO). MO can cause irreversible tissue damage and permanent visual impairment. Dexamethasone implant is approved for intravitreal injection (IV) in the treatment of MO. Despite its proven efficacy, IV poses risks of complications. Recently, suprachoroidal injection has emerged as a novel strategy for targeted drug delivery to the posterior segment of the eye, reducing the risk of complications.Case presentationA 70-year-old woman with no history of diabetes underwent left eye cataract surgery complicated by a capsular rupture and vitreous prolapse, which resulted in the patient becoming aphakic. Later, ophthalmic examination revealed a cystoid MO secondary to a posterior postoperative NIU. Since IV injection of triamcinolone had minimal visual benefit and due to the contraindication of IV cortisone implants, a dexamethasone implant was injected via the suprachoroidal injection, with additional intravitreal triamcinolone. Functional and anatomical recovery was observed after the procedure, with improved visual acuity and no ocular hypertension.ConclusionOur study describes a successful case of dexamethasone implant administered via suprachoroidal space, with no complications and a possible increased effectiveness when compared with intravitreal triamcinolone.</p>","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":" ","pages":"11206721251337634"},"PeriodicalIF":1.4,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ocular surface squamous neoplasia: Growth, diagnosis, and treatment.","authors":"Xi Lan, Zhiwen Xie, Xie Fang, Shunrong Luo, Xianwen Xiao, Yuan Lin, Zhirong Lin, Huping Wu","doi":"10.1177/11206721251337166","DOIUrl":"https://doi.org/10.1177/11206721251337166","url":null,"abstract":"<p><p>BackgroundOcular surface squamous neoplasia (OSSN) is the most common malignancy of the ocular surface, often presenting as a non-pigmented lesion with atypical squamous epithelialization. It is usually asymptomatic and can be confused with benign conditions such as pterygium or conjunctival cysts. If untreated, OSSN may progress to invasive squamous cell carcinoma, causing vision loss or metastasis. The gold standard for diagnosing OSSN is histopathological examination after tumor resection. However, there are still unresolved issues in the clinical management of treatment.Main textIn this review, we have discussed the clinical characteristics, diagnostic techniques, and treatment options for OSSN. OSSN occurs due to changes in the living environment and ocular surface state. It starts as a benign squamous epithelial tumor, which can progress to atypical intraepithelial neoplasia and eventually turn into invasive squamous cell carcinoma. The postoperative pathological histology also shows a corresponding degree of differentiation. Various diagnostic techniques, such as diagnostic imaging, cell biology, and molecular biology, are emerging as valuable tools for distinguishing OSSN. Although surgical resection is the primary treatment for OSSN, drug therapy can also be applied for better management of OSSN treatment.ConclusionAccurately diagnosing OSSN requires advanced examination techniques before and after operation. This is crucial for healthcare professionals to evaluate and treat the condition effectively. Based on our clinical expertise, administering drug treatment before or after surgical resection may serve as a comprehensive and effective management approach for OSSN. This research holds immense potential for the future of personalized and precise medical care.</p>","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":" ","pages":"11206721251337166"},"PeriodicalIF":1.4,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic factors of intracorneal rings segment to a successful treatment and probability of success calculation.","authors":"Loïc Dambricourt, Gaëlle Ho Wang Yin, Natanaël Levy, Danièle Denis, Thierry David","doi":"10.1177/11206721251331662","DOIUrl":"https://doi.org/10.1177/11206721251331662","url":null,"abstract":"<p><p>PurposeTo identify prognostic factors for the success of intracorneal rings segment (ICRS) implantation in keratoconus, define a \"good responder\" patient, and estimate the probability of success of the intervention.MethodsIn this retrospective study, 130 eyes underwent ICRS implantation with Keraring and Intacs SK. Refractive, topographic, and aberrometric variables were measured before and after intervention, then patients were classified into \"success\" and \"failure\" groups based on postoperative refractive and aberrometric data. Univariate and multivariate analysis were performed to identify prognostic factors and develop a calculation formula for probability of success.ResultsSuccess was observed in 64.6% of patients while 35.4% experienced failure. In the success group, corrected distance visual acuity (CDVA) in logMAR was higher (0.38 ± 0.23 vs 0.28 ± 0.21, p = 0.03), corneal asphericity (Q-value) was less prolate (-0.92 ± 0.43 vs -1.10 ± 0.40; p = 0.009), and distance between Kmax and center of pupil (DKmax) was higher (1.65 ± 0.83 vs 1.35 ± 0.70; p = 0.045). Maximal keratometry (Kmax) was lower (58.38 ± 4.83 vs 59.86 ± 4.42; p = 0.068) and spherical equivalent (SE) was more negative (-3.77 ± 3.20 vs -3.05 ± 3.65; p = 0.09) but not statistically significant. With a logistic regression model, we created a calculation formula of the probability of success including keratoconus stage, CDVA, uncorrected distance visual acuity (UDVA), SE, Kmax, Q-Value and DKmax.ConclusionsICRS implantation has a higher chance of success in stage III keratoconus, eccentric, with myopic astigmatism, visual loss, Q-Value close to zero and low Kmax. The calculation of the probability of success helps to select patients for surgery.</p>","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":" ","pages":"11206721251331662"},"PeriodicalIF":1.4,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toward comprehending uncommon periocular manifestations: A case of localized AL amyloidosis with a rare spontaneous eyelid ecchymosis.","authors":"Caio Brenno Abreu, Bárbara Flores Culau Merlo, Márcio Penha Morterá Rodrigues, Fernanda Galante Dourado, Tullia Cuzzi Teichner, Danielle Carvalho Quintella, Denize D'Azambuja Ramos, Juliana de Sá Freire Medrado Dias","doi":"10.1177/11206721251333603","DOIUrl":"https://doi.org/10.1177/11206721251333603","url":null,"abstract":"<p><p>IntroductionAmyloidosis, characterized by extracellular protein misfolding and deposition. Localized immunoglobulin light chain amyloidosis can present with atypical features.Case presentationThis case report elucidates an unconventional manifestation of localized immunoglobulin light chain amyloidosis characterized by recurrent and spontaneous eyelid ecchymosis alternating with episodes of incomplete resolution, a novelty in current literature, along with associated cutaneous changes.DiscussionThis rare presentation underscores the importance of considering amyloidosis in the differential diagnosis of unusual periocular findings and may assist in identifying similar cases of atypical eyelid amyloidosis, especially in cases with limited involvement, promoting early diagnosis and intervention.</p>","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":" ","pages":"11206721251333603"},"PeriodicalIF":1.4,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the overlooked risk: Ocular health and alterations in women with polycystic ovary syndrome.","authors":"Harshita Pandey, Neha Sharma, Kritika, Md Aftab Alam","doi":"10.1177/11206721251337584","DOIUrl":"10.1177/11206721251337584","url":null,"abstract":"<p><p>BackgroundPolycystic Ovary Syndrome is well known to cause various metabolic changes in the body; however, changes in the ocular surface are not fully understood or well-described in the existing literature. Hormonal disturbances resulting from PCOS may affect multiple ocular tissues, including the posterior segment, lacrimal and meibomian glands, cornea, and conjunctiva.ObjectiveThis paper aims to summarize the current knowledge and research regarding ocular alterations related to PCOS.MethodA comprehensive review of the existing literature was conducted by searching multiple databases, including Scopus, PubMed, and Google Scholar. Keywords such as \"Polycystic Ovary Syndrome,\" \"PCOS,\" \"ocular surface,\" \"dry eye,\" \"meibomian gland dysfunction,\" and \"ocular changes\" were used. Relevant case reports and clinical studies were included to provide a comprehensive understanding of the ocular implications of PCOS.ResultsAmong the ocular changes associated with PCOS, dry eyes are the most common source of irritation and discomfort in affected individuals. Recognizing this association is crucial for eye care practitioners.ConclusionIdentifying the link between PCOS and dry eyes enables practitioners to develop personalized management plans for individuals with PCOS, potentially improving their eye health and comfort in longer run. When necessary, further evaluation or referral may be required for patients with PCOS-related ocular symptoms.</p>","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":" ","pages":"11206721251337584"},"PeriodicalIF":1.4,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144003894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optogenetic therapy for retinal degenerative diseases: A review.","authors":"Ehab Kasem, Masa Watfa, Ali Afif, Raghad Hasan, Majd Mansour, Haya Almhmoud, Basem Zaino","doi":"10.1177/11206721251335560","DOIUrl":"https://doi.org/10.1177/11206721251335560","url":null,"abstract":"<p><p>Optogenetics, a cutting-edge tool in novel gene manipulation and drug discovery, holds significant therapeutic potential for a variety of neurological disorders, including retinal diseases. Retinal diseases such as age-related macular degeneration (AMD) and retinitis pigmentosa (RP), significantly impair quality of life and cause severe visual impairment due to limited treatment options and a general lack of awareness. The increasing incidence of these degenerative conditions underscores the need for innovative solutions, such as optogenetics. Optogenetic therapy introduces genes coding for light-sensitive proteins, which are controlled by light signals to make neurons photosensitive. This precise targeting approach does not require specific gene intervention and can bypass dysfunctional photoreceptors, offering a treatment option for various degenerative and dystrophic eye diseases. Successful outcomes in patients with late-stage genetic retinal diseases and numerous clinical trials suggest that optogenetics could be an effective treatment for humans. This review provides an overview of the current landscape of optogenetic therapy, discusses its challenges, and summarizes the findings of ongoing clinical trials for neural and visual restoration.</p>","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":" ","pages":"11206721251335560"},"PeriodicalIF":1.4,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The presence of stem cells in the human lacrimal drainage system: A proof of principle study.","authors":"Tejaswini Pingali, Dilip K Mishra, Vivek Singh, Mohammad Javed Ali","doi":"10.1177/11206721251333826","DOIUrl":"https://doi.org/10.1177/11206721251333826","url":null,"abstract":"<p><p>PurposeTo investigate the presence of stem cells within the lacrimal drainage system.MethodsA prospective interventional case series where human lacrimal sac tissue biopsies were obtained from patients undergoing endoscopic dacryocystorhinostomy or a dacryocystectomy surgery at a tertiary care Dacryology Services. Histopathology, immunohistochemistry, and gene expression studies were performed to check the expression of several basic stem/progenitor specific genes - <i>Cd90, Cd105, Cd73</i>, <i>Abcb5, Abcg2,</i> and <i>P63α.</i>ResultsThe lacrimal sac showed positive expression of general stem cell markers (ABCB5, ABCG2, and P63<i>α)</i> and mesenchymal stem cell-specific markers <i>(CD73, CD90, CD105)</i> using transcriptional and immunolocalization studies<i>.</i> Interestingly, CD73 and CD105 double-positive cells and CD73 and CD90 double-positive cells (specific markers for mesenchymal stem cells) were noted in the lacrimal sac stroma and were confirmed not to be vascular endothelial cells.ConclusionThe present study is proof of the principle of the presence of a wide range of stem cell markers within the human lacrimal sac. This study could serve as a foundation for investigating the stem cells and characterizing them further to better understand the lacrimal drainage disorders.</p>","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":" ","pages":"11206721251333826"},"PeriodicalIF":1.4,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Continuous wave transscleral cyclophotocoagulation with the slow-cooking protocol to treat refractory glaucomas.","authors":"Heloisa Andrade Maestrini, Heloisa Helena Abil Russ, Regina Cele Silveira Seixas, Marcos Balbino, Thatiana Almeida Pereira Fernandes, Núbia Vanessa Lima, Nara Lídia Vieira Lopes, Luiz Paulo Dias Mario, Taurino Dos Santos Rodrigues Neto","doi":"10.1177/11206721251335381","DOIUrl":"https://doi.org/10.1177/11206721251335381","url":null,"abstract":"<p><p>PurposeThis study aimed to describe the results of slow-cooking transscleral cyclophotocoagulation (SC-TSCP) with diode laser in patients with refractory glaucoma.MethodsThis retrospective study included 289 eyes of 263 patients who underwent the SC-TSCP technique at the glaucoma service of Oculare Ophthalmology Hospital, Brazil, with a minimum of one year of postoperative follow-up. We analyzed intraocular pressure, number of medications, postoperative complications, visual acuity, need for additional glaucoma surgery, need for repeat sessions of SC-TSCP, and the variables influencing success rates. ​​We used three criteria to analyze the technique's success: 1) Final IOP ≤ 21 mmHg, 2) Final IOP between 6 and 21 mmHg, and 3) Reduction of at least 30% in IOP.ResultsMean IOP dropped from 37.52 (±12.12) mmHg preoperatively to 14.48 (± 7.56) mmHg at the end of the study (<i>p</i> = 0.0001). The average reduction in IOP was 23.04 (±14.00) mmHg, representing a reduction of 61.41% in IOP (<i>p</i> = 0.0001). The mean number of medications dropped from 2.98 (±1.43) to 1.79 (±1.50) (<i>p</i> = 0.0001). Complete success (without eyedrops) was achieved in 25.61%, 18.69%, and 29.41% for each success criterion, and qualified success (with or without eyedrops) was achieved in 79.58%, 68.86%, and 85.43%, respectively. Visual acuity decreased from 1.99 LogMar (Snellen 20/1954) to 2.11 LogMar (Snellen 20/2576) (<i>p</i> = 0.0001). Seventy-two eyes (24.91%) needed a second session, 15 eyes (5.19%) needed a third cyclophotocoagulation, and one eye (0.35%) needed a fourth session. The most common complications were persistent hypotony (8.65%), corneal decompensation (6.23%), loss of light perception (5.88%), and phthisis (2.77%). After cyclophotocoagulation, 86.85% of the eyes did not require additional surgical procedures for IOP control.ConclusionThe slow-cooking transscleral cyclophotocoagulation technique proved highly effective in the prolonged control of intraocular pressure in severe and refractory glaucoma and demonstrated a favourable safety profile. However, in complex and refractory cases, severe complications such as vision loss or phthisis, although rare, may occur.</p>","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":" ","pages":"11206721251335381"},"PeriodicalIF":1.4,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Customized treatment for myopic traction maculopathy based on the MTM staging system: Long-term results in naïve eyes.","authors":"Barbara Parolini, Veronika Matello, Michele Palmieri, Radina Kirkova, Matteo Ripa","doi":"10.1177/11206721251335390","DOIUrl":"https://doi.org/10.1177/11206721251335390","url":null,"abstract":"<p><p>PurposeTo explore the long-term anatomical and functional outcomes in naïve patients with Myopic Traction Maculopathy (MTM) treated with either macular buckle (MB) plus pars plana vitrectomy (PPV) or primary MB as unique treatment according to MTM Staging System (MSS).MethodsRetrospective study involving 206 consecutive naïve patients with MTM who underwent either MB plus PPV or primary MB. Postoperative anatomical and functional outcomes, including the MTM stage and its progression, axial length (AL), and best-corrected visual acuity (BCVA) changes, were evaluated at one month (i.e., \"early follow-up\"), six months (i.e., intermediate follow-up\"), 12 months postoperatively (i.e., \"late follow-up\") and at last follow-up ranging between 12 and 156 months postoperatively (i.e., \"final follow-up\").ResultsRetinal and foveal anatomical results significantly improved in patients who underwent either primary MB plus PPV or MB (<i>p</i> < 0.001), with 100% and 92.1% of patients who underwent complete resolution, respectively. For every MTM stage, the BCVA significantly improved over the follow-up visits. (<i>p</i> < 0.001). At the last visit, 84 (41%) eyes improved to 0.5 decimal or more. In patients treated before 2020, when applying more combined PPV treatments, there was a high rate of early iatrogenic full-thickness macular holes (<i>p</i> = 0.005). The results obtained since 2020, when the customized treatment was employed, led to better results without sight-threatening complications.ConclusionsThe MTM Staging System should be the foundation for treating MTM. It should precisely assess the optimal surgical technique and the ideal time to perform it concerning the various stages to maximize anatomical and functional success.</p>","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":" ","pages":"11206721251335390"},"PeriodicalIF":1.4,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}